Effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome: final analysis of the UK randomised placebo-controlled trial.

Abstract

The UK Turner syndrome (TS) study examined the effect on final height of oxandrolone 0.05 mg/kg/day (maximum dose 2.5 mg) versus placebo from 9 years of age; and delaying ethinylestradiol induction of puberty by 2 years from 12 (E12) to 14 (E14) years in growth hormone-treated girls with TS. The study ran from 1999 to 2013. By 2011, eighty-two of 92 participants had reached final height and an interim analysis using the Super-Imposition by Translation And Rotation model showed significant increases in final height with both oxandrolone and E14. The analysis has been repeated now that all 92 patients have reached final height. Oxandrolone still significantly increased final height by 4.1 cm (95% CI 1.6 to 6.6, n=92) compared with 4.6 cm previously. However, the E14 effect was no longer significant at 2.7 cm (95% CI -0.8 to 6.1, n=56) compared with 3.8 cm previously.

• Authors: Emma Jane Gault, Tim J Cole, Sarah Casey, Peter C Hindmarsh, Peter Betts, David B Dunger, Malcolm D C Donaldson
• Journal: Archives of disease in childhood (Arch Dis Child) Vol. 106 Issue 1 Pg. 74-76 (01 2021) ISSN: 1468-2044 [Electronic] England
• PMID: 31862699 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Anabolic Agents
• Oxandrolone

Topics

• Anabolic Agents (administration & dosage, therapeutic use)
• Body Height
• Child
• Drug Administration Schedule
• Female
• Humans
• Male
• Oxandrolone (administration & dosage, therapeutic use)
• Treatment Outcome
• Turner Syndrome (drug therapy)
• United Kingdom